• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肤色性银屑病:非白种人种族/族群的银屑病流行病学、临床表现、遗传学、生活质量影响和治疗的见解。

Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.

机构信息

Mount Sinai St. Luke's, 1090 Amsterdam Avenue, Suite 11B, New York, NY, 10025, USA.

出版信息

Am J Clin Dermatol. 2018 Jun;19(3):405-423. doi: 10.1007/s40257-017-0332-7.

DOI:10.1007/s40257-017-0332-7
PMID:29209945
Abstract

Psoriasis is a chronic inflammatory skin condition affecting diverse racial/ethnic groups throughout the world. Large population-based studies suggest that psoriasis occurs most often in individuals of European ancestry, followed by black and Hispanic individuals, although the true prevalence of psoriasis in non-white individuals is likely underestimated. Despite similarities in psoriasis between ethnic groups, there are notable differences in the presentation, quality-of-life impact, and treatment of psoriasis with important implications for the management of non-white individuals. Overall, heterogeneity in psoriasis susceptibility alleles, in combination with cultural and socioeconomic factors, may explain these differences. In this article, we review the epidemiology, clinical presentation, genetic polymorphisms, quality-of-life impact, and treatment nuances of psoriasis in patients with skin of color.

摘要

银屑病是一种慢性炎症性皮肤疾病,影响着世界各地不同种族/民族的人群。基于人群的大型研究表明,银屑病最常发生在欧洲血统的个体中,其次是黑人和西班牙裔个体,尽管非白种人群中银屑病的真实患病率可能被低估了。尽管不同种族之间的银屑病存在相似之处,但在其表现、对生活质量的影响以及治疗方面存在显著差异,这对非白种人群的管理具有重要意义。总的来说,银屑病易感等位基因的异质性,加上文化和社会经济因素,可能解释了这些差异。在本文中,我们综述了有色人种患者银屑病的流行病学、临床表现、遗传多态性、对生活质量的影响以及治疗特点。

相似文献

1
Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.肤色性银屑病:非白种人种族/族群的银屑病流行病学、临床表现、遗传学、生活质量影响和治疗的见解。
Am J Clin Dermatol. 2018 Jun;19(3):405-423. doi: 10.1007/s40257-017-0332-7.
2
Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects.掌跖银屑病和掌跖脓疱病:当前治疗方法与未来展望
Am J Clin Dermatol. 2016 Aug;17(4):349-58. doi: 10.1007/s40257-016-0191-7.
3
Psoriasis & psoriatic therapies.银屑病与银屑病治疗
Nurse Pract. 2017 Jul 15;42(7):35-39. doi: 10.1097/01.NPR.0000520419.09460.ad.
4
Genital Psoriasis: Impact on Quality of Life and Treatment Options.生殖器银屑病:对生活质量的影响和治疗选择。
Am J Clin Dermatol. 2019 Oct;20(5):639-646. doi: 10.1007/s40257-019-00447-5.
5
[Psoriasis--clinical picture and current therapy].[银屑病——临床表现与当前治疗方法]
Med Monatsschr Pharm. 2009 Sep;32(9):335-44; quiz 345-6.
6
[Psoriasis].[银屑病]
Ther Umsch. 2010 Apr;67(4):153-65. doi: 10.1024/0040-5930/a000029.
7
Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs.目前针对银屑病的治疗方法及未来展望——聚焦于血清素能药物。
Mol Neurobiol. 2020 May;57(5):2391-2419. doi: 10.1007/s12035-020-01889-3. Epub 2020 Feb 15.
8
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.银屑病患者生物治疗的主要不良心血管事件风险评估
J Drugs Dermatol. 2017 Oct 1;16(10):1002-1013.
9
Modern concepts of the diagnosis and treatment of psoriasis.银屑病诊断与治疗的现代概念
J Environ Pathol Toxicol Oncol. 2009;28(3):235-40. doi: 10.1615/jenvironpatholtoxicoloncol.v28.i3.50.
10
TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey.土耳其银屑病患者生活质量与治疗状况的横断面研究:TUR - PSO
J Dermatol. 2016 Mar;43(3):298-304. doi: 10.1111/1346-8138.13081. Epub 2015 Sep 14.

引用本文的文献

1
The Effect of Stigmatization on Working Nurses' Willingness to Care for Patients with Psoriasis and Its Mediating Factors.污名化对在职护士护理银屑病患者意愿的影响及其中介因素
Acta Derm Venereol. 2025 Sep 10;105:adv43662. doi: 10.2340/actadv.v105.43662.
2
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial.古塞库单抗用于治疗各种肤色的中度至重度银屑病:VISIBLE随机临床试验的A队列
JAMA Dermatol. 2025 Jun 25. doi: 10.1001/jamadermatol.2025.1836.
3
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.
古塞库单抗用于治疗所有肤色的中度至重度头皮银屑病:VISIBLE随机临床试验的队列B
JAMA Dermatol. 2025 Jun 25. doi: 10.1001/jamadermatol.2025.1849.
4
Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry.生物治疗起始个体中按基线体表面积受累情况报告的患者结局:来自CorEvitas银屑病注册研究的结果
Dermatol Ther (Heidelb). 2025 Jun 11. doi: 10.1007/s13555-025-01456-5.
5
Probiotics and gut microbiota modulation: implications for skin health and disease management.益生菌与肠道微生物群调节:对皮肤健康和疾病管理的影响。
Arch Microbiol. 2025 Feb 23;207(3):68. doi: 10.1007/s00203-025-04267-6.
6
Optimizing the management of psoriasis in patients with skin of color: A Canadian Delphi consensus.优化有色人种银屑病患者的管理:加拿大德尔菲共识。
JAAD Int. 2024 Nov 14;19:12-20. doi: 10.1016/j.jdin.2024.09.015. eCollection 2025 Apr.
7
Psoriasis in People With Skin of Color: An Evidence-Based Update.有色人种的银屑病:基于证据的最新进展
Int J Dermatol. 2025 Apr;64(4):667-677. doi: 10.1111/ijd.17651. Epub 2025 Jan 31.
8
Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement.在一项新型银屑病研究中提高多样性:VISIBLE作为临床试验质量改进的框架
JAMA Dermatol. 2025 Mar 1;161(3):256-264. doi: 10.1001/jamadermatol.2024.5103.
9
Mapping the psoriasis research landscape: A comprehensive bibliometric analysis from 2012-2023.绘制银屑病研究图谱:2012-2023 年的全面文献计量分析。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241290341. doi: 10.1177/03946320241290341.
10
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.一项关于司库奇尤单抗在不同种族和族裔中重度银屑病患者群体中的疗效和安全性的描述性事后分析。
Dermatol Ther (Heidelb). 2024 Oct;14(10):2877-2887. doi: 10.1007/s13555-024-01268-z. Epub 2024 Oct 2.